180 related articles for article (PubMed ID: 33773807)
1. Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
Filippova OT; Tin AL; Alonso J; Vickers AJ; Tew WP; Gardner GJ; Sonoda Y; Roche KL; Zivanovic O; Chi DS; Shahrokni A
Gynecol Oncol; 2021 Jun; 161(3):687-692. PubMed ID: 33773807
[TBL] [Abstract][Full Text] [Related]
2. The Frailty Based on the Memorial Sloan Kettering Frailty Index for Prediction of Surgical Outcome in Advance Epithelial Ovarian Cancer-Experience of a Single Center in Mexico.
Aguilar-Frasco JL; Armillas-Canseco F; Rivera-Sánchez F; Moctezuma-Velázquez P; Moctezuma-Velázquez C; Castro E; Pastor-Sifuentes FU; Hernández-Gaytán CA; Alfaro-Goldaracena A; Medina-Franco H
Indian J Surg Oncol; 2022 Jun; 13(2):426-431. PubMed ID: 35782793
[TBL] [Abstract][Full Text] [Related]
3. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
Kumar A; Langstraat CL; DeJong SR; McGree ME; Bakkum-Gamez JN; Weaver AL; LeBrasseur NK; Cliby WA
Gynecol Oncol; 2017 Oct; 147(1):104-109. PubMed ID: 28734497
[TBL] [Abstract][Full Text] [Related]
4. Development and Evaluation of a New Frailty Index for Older Surgical Patients With Cancer.
Shahrokni A; Tin A; Alexander K; Sarraf S; Afonso A; Filippova O; Harris J; Downey RJ; Vickers AJ; Korc-Grodzicki B
JAMA Netw Open; 2019 May; 2(5):e193545. PubMed ID: 31074814
[TBL] [Abstract][Full Text] [Related]
5. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
Narasimhulu DM; McGree ME; Weaver AL; Jatoi A; LeBrasseur NK; Glaser GE; Langstraat CL; Block MS; Kumar A
Gynecol Oncol; 2020 Sep; 158(3):646-652. PubMed ID: 32518016
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
7. Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery.
Yao T; DeJong SR; McGree ME; Weaver AL; Cliby WA; Kumar A
Gynecol Oncol; 2019 Apr; 153(1):68-73. PubMed ID: 30612784
[TBL] [Abstract][Full Text] [Related]
8. Preoperative frailty vs. cognitive impairment: Which one matters most for postoperative delirium among older adults with cancer?
Hoffmann AJ; Tin AL; Vickers AJ; Shahrokni A
J Geriatr Oncol; 2023 May; 14(4):101479. PubMed ID: 37001348
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
[TBL] [Abstract][Full Text] [Related]
10. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM; Filippova OT; Cowan RA; Lakhman Y; Sarasohn DM; Nikolovski I; Torrisi JM; Ma W; Abu-Rustum NR; Gardner GJ; Sonoda Y; Zivanovic O; Chi DS; Long Roche K
Gynecol Oncol; 2020 Sep; 158(3):608-613. PubMed ID: 32518012
[TBL] [Abstract][Full Text] [Related]
11. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
[TBL] [Abstract][Full Text] [Related]
12. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
[TBL] [Abstract][Full Text] [Related]
13. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
14. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
Narasimhulu DM; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
Gynecol Oncol; 2019 Oct; 155(1):58-62. PubMed ID: 31402165
[TBL] [Abstract][Full Text] [Related]
15. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
Boerner T; Filippova OT; Chi AJ; Iasonos A; Zhou QC; Long Roche K; Zivanovic O; Park BJ; Huang J; Jones DR; Abu-Rustum NR; Gardner G; Sonoda Y; Chi DS
Gynecol Oncol; 2020 Oct; 159(1):66-71. PubMed ID: 32792282
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
17. Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
Dahm-Kähler P; Holmberg E; Holtenman M; Rådestad AF; Borgfeldt C; Hjerpe E; Marcickiewicz J; Bjurberg M; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E; Stålberg K
Gynecol Oncol; 2021 Apr; 161(1):244-250. PubMed ID: 33581846
[TBL] [Abstract][Full Text] [Related]
18. Preoperative frailty predicts postoperative falls in older patients with cancer.
Meckstroth S; Tin AL; Downey RJ; Korc-Grodzicki B; Vickers AJ; Shahrokni A
J Geriatr Oncol; 2024 Mar; 15(2):101688. PubMed ID: 38141587
[TBL] [Abstract][Full Text] [Related]
19. Effect of frailty on postoperative readmissions and cost of care for ovarian cancer.
Sia TY; Wen T; Cham S; Friedman AM; Wright JD
Gynecol Oncol; 2020 Nov; 159(2):426-433. PubMed ID: 32868087
[TBL] [Abstract][Full Text] [Related]
20. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
